Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib adaptive platform study of targeted drug combinations in BRAF V600 advanced or metastatic colorectal cancer
NL-OMON52799Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dabrafenib + trametinib, rineterkib, trametinib, naporafenib, batoprotafib and 2 more in colorectal cancer (CRC), sponsored by Novartis. Primary endpoints: Incidence and severity of adverse events and serious adverse events, Dose-limiting toxicities and 1 more. Started Jul 2021; status: active, not recruiting.
02
Drugs
dabrafenib + trametinibrineterkibtrametinibnaporafenibbatoprotafib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON52799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52799.